ClinicalTrials.gg
CompletedNCT03378284Updated Mar 30, 2018

A Study to Evaluate Safety, Tolerability, and PD of Tegoprazan on Healthy Male Volunteers

A Phase 1 interventional study of Tegoprazan and Revaprazan in Pharmacodynamics and Healthy Male Volunteers, sponsored by HK inno.N Corporation. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-30.

Sponsored by HK inno.N Corporation · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
Male
01

Study summary

A randomized, open-label, active-controlled, multiple dose phase 1 clinical trial to evaluate safety, tolerability, and pharmacodynamics of tegoprazan after oral administration in healthy male volunteers

Read the detailed description
  • To compare the pharmacodynamics of multiple oral dose of tegoprazan versus the pharmacodynamics of multiple oral dose of comparator drug in healthy male volunteers.
  • To evaluate the safety and tolerability of multiple oral dose of tegoprazan in healthy male volunteers.
02

Conditions studied

  • Pharmacodynamics
  • Healthy Male Volunteers
03

In context

Lead sponsor

HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult males aged ≥ 19 years and ≤ 50 years
  • Body weight of ≥ 55.0 kg and ≤ 90.0 kg, with (BMI) of ≥ 18.0 kg/m2 and ≤ 27.0 kg/m2 at the time of screening

Exclusion criteria

Exclusion Criteria:

  • Presence or history of diseases
  • Presence or history of gastrointestinal disorder (gastric ulcer, GERD, Crohn's disease, etc.)
  • to drugs containing study drug or proton pump inhibitor and other drugs (aspirin, antibiotics, etc.) or history of clinically significant hypersensitivity
  • Serologic test positive
  • Abnormal obstacle to insertion and maintenance of pH meter catheter
  • History of drug abuse
  • Excessive caffeine intake or persistent alcohol intake
  • Not use of a medically acceptable method of
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Tegoprazan(Test drug)

    Tegoprazan drug QD for 7 days

    Drug: Tegoprazan

  • Active comparator
    Active comparator drug

    Active comparator drug QD for 7 days

    Drug: Revaprazan

Interventions

  • Tegoprazan QD for 7 days

  • DrugRevaprazan

    Revaprazan QD for 7 days

06

What researchers measure

Primary outcomes

  1. Gastric pH

    Gastric pH

    Time frame: up to 7 days

  2. Serum gastrin concentration

    Serum gastrin concentration

    Time frame: up to 9 days

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Dec 2017, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2017
First posted
Dec 19, 2017
StartActual
Dec 10, 2017
Primary completionActual
Dec 23, 2017
CompletionActual
Jan 16, 2018
Last update
Mar 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03378284
Responsible party
Sponsor
First posted
Dec 19, 2017
Start date
Dec 10, 2017
Primary completion
Dec 23, 2017
Completion
Jan 16, 2018
Last update
Mar 30, 2018

Study contacts

In Jin Jang, MD, PhD
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprazan

Start the discussion